Barclays Maintains Overweight on Cytokinetics, Lowers Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Cytokinetics (NASDAQ:CYTK) but lowers the price target from $100 to $95.
May 23, 2024 | 3:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Cytokinetics but lowers the price target from $100 to $95.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100